Building Trusted AI at Scale Cities Startups & Digital Sovereignty – Keynote Kiran Mazumdar-Shaw
20 Feb 2026 12:00h - 13:00h
Building Trusted AI at Scale Cities Startups & Digital Sovereignty – Keynote Kiran Mazumdar-Shaw
Summary
Kiran Mazumdar-Shaw opened the Impact AI Summit by emphasizing that the coming decades will be defined by “biotech sovereignty embedded in AI” rather than digital sovereignty, and that nations mastering the convergence of biological and artificial intelligence will shape future health, food security, sustainability and biosecurity [2-4][5]. For India, this convergence is not merely an opportunity but a strategic and geopolitical imperative, linking scientific leadership to national resilience [6-8].
She defined biological intelligence as the product of 3.8 billion years of evolution, where living cells sense, compute and act through intricate signaling networks and built-in guardrails that maintain homeostasis, and illustrated this with the immune system’s ability to store pathogen information in memory cells and launch rapid, energy-efficient responses without large data centers [9-16][19-25]. The migratory precision of the Arctic tern, driven by DNA-encoded navigation, serves as another example of innate biological intelligence, contrasting with AI that learns from external data [29-33].
Mazumdar-Shaw highlighted that AI can accelerate protein-structure prediction, generative drug design, digital twins of cells, and ultimately enable reprogramming of cells to restore biological balance, while AI-driven mapping of regulatory circuits allows interventions that preserve homeostasis and shift biotech from disease management to system re-engineering [36-43][50-52]. She warned that reliance on offshore AI models for drug discovery and genomics would create strategic dependence, making sovereign control over data, models and infrastructure essential for health security [54-57].
To achieve this, she called for a “triple helix” of government investment in sovereign AI bio-infrastructure, academia development of computational-biology curricula, and industry co-creation of shared platforms and biomanufacturing clusters, noting that regulations must keep pace with rapid AI-driven timelines to avoid missed opportunities [71-77][68-70]. Ethical, transparent, energy-efficient and bias-aware AI systems rooted in public interest are presented as India’s unique model for global interoperability and social purpose [82-86]. Concluding, Mazumdar-Shaw asserted that India possesses the scientific talent, AI expertise and values to lead in biotech sovereignty, provided it builds sovereign platforms today, thereby securing health, strategic autonomy and economic resilience [90-91].
Keypoints
Major discussion points
– Biotech sovereignty + AI is a strategic, geopolitical imperative for India.
Mazumdar-Shaw frames the need for “biotech sovereignty that is embedded in AI” as essential to national resilience, health security and economic competitiveness, warning that reliance on offshore AI models creates strategic dependence [3-5][6-8][54-57].
– Biological intelligence is a model for AI-driven innovation.
She describes living systems as “the original intelligent machines” that learn, store, retrieve and act on information with extreme energy efficiency, using examples such as immune memory and Arctic-tern navigation to illustrate how biology processes data far beyond today’s data-center capabilities [9-15][19-25][29-34][36-38].
– A full-stack AI-enabled biotech ecosystem is required, spanning discovery, development, manufacturing and regulation.
The speaker outlines concrete AI applications – foundation models for proteins/RNA, in-silico trials, digital twins, smart biomanufacturing, AI-validated regulatory pathways – and stresses the need for sovereign data, computing infrastructure and translational platforms [60-68][70-77].
– Triple-helix collaboration and ethical, transparent AI are essential for global leadership.
She calls for coordinated action among government, academia and industry (the “triple helix”) together with capital markets, and stresses that India’s AI-bio systems must be energy-efficient, bias-aware and interoperable, embedding equity, affordability and public-interest values [71-76][81-86].
– Realised AI-bio sovereignty will deliver health, longevity and economic benefits while mitigating risks.
By re-programming cells, extending health-span, and creating AI-native discovery engines, India can shift from “managing disease” to “re-engineering biological systems,” securing a 50-year-plus lifespan for its citizens and positioning the country as a global biotech platform [48-53][89-90].
Overall purpose / goal
The talk is a strategic appeal to policymakers, industry leaders, academia and investors to accelerate the creation of an Indian-owned, AI-driven biotech infrastructure. It seeks to convince the audience that building sovereign AI models, data assets and biomanufacturing capabilities is vital for national health security, economic resilience, and to claim a leadership role in the emerging convergence of biology and artificial intelligence.
Overall tone
The tone begins with enthusiastic optimism (“delighted…heralds a big signal”) and a visionary framing of AI-biotech convergence. It then moves into a more urgent, persuasive register when stressing strategic imperatives and risks of external dependence. Mid-speech the tone becomes technical and explanatory, detailing how biological intelligence works. In the latter part it shifts to a rallying, call-to-action tone, urging coordinated “triple-helix” effort and ethical stewardship, and concludes on an inspirational, confident note about India’s capacity to lead the future of humanity.
Speakers
– Speaker 1 – Role/Title: Event moderator or host introducing the main speaker (appears to be an event host)[S1][S3].
Areas of expertise: (not specified)
– Kiran Mazumdar-Shaw – Role/Title: Chairperson, Biocon Group[S4].
Areas of expertise: Biotechnology, healthcare innovation, AI-enabled drug discovery, biotech sovereignty, life-sciences entrepreneurship.
Additional speakers:
– None.
Ladies and gentlemen were invited to applaud the arrival of Ms Kiran Mazumdar-Shaw, Chairperson of the Biocon Group [1][2]. She opened by expressing delight at taking part in the inaugural Impact AI Summit, signalling India’s entry onto the global AI journey.
Mazumdar-Shaw situated the summit’s theme within a geopolitical narrative. She argued that the 20th century was defined by the Internet, the early 21st century by digital sovereignty, and that the coming decades will be shaped by “biotech sovereignty embedded in AI” [4]. Nations that master the convergence of biological intelligence and artificial intelligence will dictate the future of healthcare, food security, education, biomanufacturing, sustainability, bio-security and many other domains [5]. For India this is not merely a cutting-edge opportunity; it is a strategic and geopolitical imperative that underpins national resilience and health security [6-8].
To explain “biological intelligence”, Mazumdar-Shaw described living systems as the original intelligent machines, honed over 3.8 billion years of evolution [9-11]. Cells sense, compute and respond through intricate signalling networks coupled to gene-regulatory circuits and immune memory, operating within built-in guardrails that maintain homeostasis [12-16]. When these guardrails fail, disease emerges [17-18]. She illustrated this with the immune system: cytokines, antibodies and killer T-cells constitute the body’s immunological ammunition, while memory B- and T-cells store pathogen identities and can launch rapid, energy-efficient responses upon re-exposure [19-22]. This biological information processing occurs at speeds and with energy consumption far below that of modern data-centres, relying on distributed, low-power “data centres” within the body and the brain-the largest known supercomputer [23-27].
A vivid example was the Arctic tern, a bird the size of a tennis ball that migrates ≈ 70 000 km between the poles without prior learning or guidance, relying on DNA-encoded navigational intelligence [29-33][??]. By contrast, conventional AI learns from external data to optimise decisions at machine scale. The true inflection point, she argued, lies at the intersection of these two forms of intelligence, where AI-powered biology can accelerate protein-structure prediction, generative drug design and the creation of digital twins of cells and organs, thereby compressing discovery timelines and reducing development risk [34-38]. She emphasized that AI by itself will not generate economic growth; the value will arise from applying AI-driven solutions in manufacturing and product delivery to create tangible economic benefits [??].
Building on this, Mazumdar-Shaw highlighted the next frontier: reprogramming cells to restore biological balance. She invited the audience to imagine converting cancer cells into non-malignant ones and repairing bone tissue that is currently irreparable, noting that such feats require deep understanding of cell signalling, gene regulation and immune memory-the same networks that maintain homeostasis [39-43][44-46]. She linked these ambitions to personalised CAR-T therapies, autoimmune-disease interventions that recalibrate immune tolerance rather than broadly suppress immunity [??], and longevity research aimed at modulating senescence, metabolic pathways of ageing and cellular repair mechanisms, which could extend human health-span by fifty years or more [47-48]. Crucially, these approaches seek to reinforce, rather than override, the innate guardrails of biology, with AI mapping regulatory circuits at scale to identify interventions that preserve homeostasis [49-52].
Mazumdar-Shaw warned that reliance on offshore foundational AI models for drug discovery, genomics, cellular engineering and clinical decision-making would create strategic dependence in the most critical domain of national resilience – human health [??]. She defined “biotech sovereignty embedded in AI” as sovereign control over trusted biological data, indigenous AI models, computing infrastructure and end-to-end translational platforms spanning discovery, development, manufacturing and delivery [56-57]. Such sovereignty is essential not only for economic competitiveness but also for preparedness against pandemics, antimicrobial resistance and emerging bio-threats [57].
To realise this vision, she outlined a full-stack AI-enabled biotech ecosystem. In discovery, India must develop foundation models for proteins, RNA, cellular circuits and systems biology [62]. In development, opportunities exist for in-silico trials, digital twins and AI-driven trial design to de-risk pipelines and improve probability of success [63]. In manufacturing, smart biomanufacturing that uses AI for yield optimisation and quality-by-design will be a key growth area [64]; she called for the development of a coordinated system of biomanufacturing, integrated with AI-enabled quality-by-design and yield-optimization [??]. In regulation, a science-first, tech-enabled pathway that integrates real-world evidence through AI validation is required, with regulatory speed matching accelerated innovation timelines [65-70]. Without coordinated regulation, the benefits of faster AI-driven discovery could be lost [68-70].
Recognising that industry alone cannot drive this transformation, Mazumdar-Shaw called for a “triple helix” of government, academia and industry:
* Government: invest in sovereign AI-bio infrastructure, trusted data architectures, regulatory sandboxes and mission-mode programmes in cell and gene therapy, immuno-oncology and longevity science [74];
* Academia: mainstream computational biology, neurosymbolic AI and AI-native life-science curricula to create a new cadre of translational scientists [75];
* Industry: co-create shared platforms, translational pipelines and globally benchmarked biomanufacturing clusters, while capital markets evolve to provide patient, long-cycle funding for high-risk biotech innovation [76-80].
Ethical considerations were woven throughout. Mazumdar-Shaw asserted that sovereignty does not mean isolation; India must build AI systems for biology that are ethical, transparent, energy-efficient and bias-aware, yet globally interoperable and rooted in the public interest [82-84]. By embedding equity, affordability and access into AI-driven biotech, the country can offer a model of innovation that couples technological leadership with social purpose [85-86].
Finally, she concluded that biotech sovereignty embedded in AI is not a sectoral ambition but the foundation of health security, strategic autonomy and economic resilience. Those who master the language of life augmented by the language of machines will shape humanity’s future, and India possesses the science, AI expertise, talent, scale and values to lead-provided it builds sovereign platforms today [87-90][91][??].
Ladies and gentlemen, please put your hands together to welcome Ms. Kiran Mazumdar -Shaw, Chairperson, Biocon Group.
Good afternoon, and let me say how delighted I am to be a part of this wonderful summit, the Impact AI Summit that India… is launching and hosting for the first time, which I think heralds a big signal that we are part of the AI journey that the world is on. I’ve basically taken off from where the last panel talked about sovereignty, and I thought I should talk about why India must build biotech sovereignty that is embedded in AI. And let me start with this first slide that basically says that if the 20th century was defined by the Internet and the early 21st century by digital sovereignty, which was all about data being the new oil and the new fuel, the coming decades, I believe, will be…
…be shaped by… biotech sovereignty that is embedded in AI. I believe that nations that command the convergence of biology and AI, or what I like to call the convergence of biological intelligence and artificial intelligence, will define the future of healthcare, food security, education, biomanufacturing, sustainability, biosecurity, and much more. For India, this is not merely a cutting -edge opportunity. It is a strategic and geopolitical imperative. Now, let me really touch upon what I mean by biological intelligence. Living systems are the original intelligent machines. And why do I say this? Because biological intelligence has evolved and has been built over 3 .8 billion years. It is different in the way it learns, memorizes, builds and processes information from multimodal signals and circuits.
Cells sense, they compute and they respond through intricate signaling networks. They also then interface with gene regulation and gene regulatory circuits and immune memory. These systems operate within inbuilt biological guardrails, which form a network of cells that are connected to each other. They focus on feedback loops and control mechanisms that maintain what we refer to as homeostasis. or health equilibrium. Disease arises when these guardrails fail. So when we talk about ethics, when we talk about governance, living systems have an inbuilt sense of guardrails and governance, which is about keeping you healthy, which is about homeostasis, which is a wonderful way of making sure that it compensates, it repairs and makes sure that you can still live in a health as healthier way as possible.
And to illustrate this, let’s look at the way our immune system responds to pathogens. The immune system responds through immunological ammunition like cytokines, antibodies and killer T cells. It also memorizes the identity of the pathogen in memory T cells and B cells. And years later, when the pathogen reinvades, the memory cells rapidly retrieve this information and translate it into instant action. This is the marvels of biology in the way it receives information, processes information, stores information, retrieves information and acts. And the inference of all this information is done at speed and with energy efficiency that we can’t even imagine. We don’t need those gigawatts of data centers. We have distributed data centers that take sips of energy when it needs to use it.
Our brain, which is the biggest supercomputer known to man, does this. So efficiently that we need to understand how biology works. Another great thought -provoking example of biological intelligence is the migration of the Arctic tern. This little bird, that is the size of a tennis ball, undertakes a 70 ,000 -kilometer journey between the Arctic, the Antarctic and back with no prior knowledge, with no older bird to guide it, and yet it does it with astonishing precision and speed. How does it do it? This is about navigational intelligence embedded in its DNA. AI, by contrast, learns from data to optimize decisions at machine scale. So therefore, the true… The true inflection point lies at their intersection. AI -powered biology…
from protein structure prediction and generative drug design to digital twins of cells and organs. AI is compressing discovery timelines and reducing development risk. And therefore, I believe that the next frontier is even more profound. The reprogramming of cells themselves to restore biological balance. But for this, we need to understand how biological intelligence operates. Imagine reprogramming cancer cells into non -malignant cells. Imagine repairing bone tissue that is damaged and irreparable. Biological intelligence is built on an intricate network of cell signaling, gene regulation and immune memory that works symbiotically, as I mentioned, to maintain homogenization. And so, we need to understand how biological intelligence operates. And so, we need to understand how biological intelligence operates. And so, we need to understand how biological intelligence operates.
now if we now come to what i’ve just spoken about which is reprogramming and re -engineering we are moving from static one -size -fits -all drugs to programmable biology which is the new frontier we need to learn how biology learns stores data retrieves and processes data in such an agile and energy efficient way once we understand the computational models of living systems we can use ai to accelerate with predictive precision the most advanced present -day therapies today we are all excited about personalized carti therapies that basically eliminate tumors with precision autoimmune disease interventions that are used to eliminate tumors with precision that recalibrate immune tolerance rather than broadly suppressing immunity And then the most exciting part of longevity and health span.
These are areas where we must understand how senescence is modulated, metabolic pathways of aging are created and cellular repair mechanisms to delay biological aging and restore tissue resilience happens. If we understand all this, as the last speaker said, we may be able to live for another 50 years and more. Flucially, these approaches seek not to overpower biology but to reinforce its inbuilt guardrails or regulatory circuits which focus on repair, feedback control and immune surveillance. AI can map these regulatory circuits at scale, enabling target interventions that preserve homeostasis. That is the excitement of new science led by AI, new biology led by AI. This represents a paradigm shift from managing disease to re -engineering biological systems to sustain equilibrium.
So, India’s future health security will depend on how optimally we combine the code of life and the code of intelligence. If foundational AI models for drug discovery, genomics, cellular engineering and clinical decision making are owned offshore, India risks strategic dependence in the market. This is the most critical domain of national resilience, which is human health. Biotech sovereignty embedded in AI must therefore mean sovereign control over trusted biological data. indigenous AI models, computing infrastructure, and translational platforms from discovery and development to manufacturing and delivery. This is essential not only for economic competitiveness, but also for preparedness against pandemics, antimicrobial resistance, and emerging new bio -threats. Now, I really believe this is a very important aspect of what AI can do for biotech and the economy.
AI alone will not create economic opportunities, but the delivery of AI in our field through manufacturing and products will do that. India’s global role must evolve from being the pharmacy of the world, to becoming the biotech platform of the world, a nation that offers AI -native discovery engines programmable therapy platforms and scalable biomanufacturing as global public goods. And this requires embedding AI across the biotech value chain. When it comes to discovery, we need to develop foundation models for proteins, RNA, cellular circuits and systems biology. When it comes to development, I think there are huge opportunities to develop in silico trials, digital twins and AI driven trial design to really de -risk the success of pipelines and probability of success.
When it comes to manufacturing, smart biomanufacturing using AI for yield optimization and most importantly, quality by design is going to be a great opportunity for all of us. Now, when it comes to the biotech value chain, we need to develop a system of biomanufacturing and also a system of biotech regulation. It has to be a science -first approach, tech -enabled regulatory pathways, integrating real -world evidence through AI validation. I think that’s going to be a huge opportunity which we must do right now. What is important is for regulations to keep up with technology. If we compress timelines of discovery and development to a fraction of what happens today, and if regulatory speed does not keep up with it, then we miss out on a huge lost opportunity.
So working in tandem, working in synchronization is the need of the hour. This transformation cannot be driven by industry alone. It demands a triple helix of government, academia and industry. Government, academia and industry. Government must invest in sovereign AI bio -infrastructure. trusted data architectures, regulatory sandboxes, and mission mode programs in cell and gene therapy, immuno -oncology, and longevity science. Academia must mainstream computational biology, neurosymbolic AI, and AI -first life sciences education to build a new cadre of translational scientists. Industry must co -create shared platforms, translational pipelines, and globally benchmarked biomanufacturing clusters that convert science into scale. Capital markets must also evolve to support long -cycle, high -risk biotech innovation that is so rampant in startups in our country.
Deep science requires a lot of research and development. It requires patient capital. But the societal and economic returns from reduced disease burden to global platform leadership are exponential. Now coming to ethics, trust and global leadership. Sovereignty is not isolation. India must build ethical, transparent, energy efficient and bias aware AI systems for biology that are globally interoperable yet rooted in public interest. And I think this is the unique model India can create. By embedding principles of equity, affordability and access into AI driven. AI. AI driven biotech, India can offer the world a new model of innovation combining technological leadership with social purpose. For India, biotech sovereignty embedded in AI is not a sectoral ambition. It is a foundation of health security, strategic autonomy and economic resilience.
Those who master the language of life augmented by the language of machines will shape the future of humanity. India has the science, the AI and life sciences talent, the scale and the values to lead provided it builds the sovereign platforms of tomorrow today. Thank you.
“Mazumdar‑Shaw positioned the summit’s theme within a geopolitical narrative, arguing that nations that master the convergence of biological intelligence and artificial intelligence will dictate the future of healthcare, food security, education, biomanufacturing, sustainability, bio‑security and many other domains”
Sources note that Mazumdar-Shaw framed the convergence of biology and AI as a geopolitical priority, stating that countries leading this intersection will shape multiple sectors including health, food, education and bio-manufacturing [S5] and [S6].
“For India this convergence is a strategic and geopolitical imperative that underpins national resilience and health security”
The knowledge base adds that her remarks emphasized national health security and the strategic importance of biotech-AI convergence for India’s resilience [S5] and [S6].
The discussion shows strong internal coherence in Kiran Mazumdar‑Shaw’s arguments, with multiple points converging on AI‑driven biotech sovereignty as essential for India’s health security, economic resilience, and global standing. The only cross‑speaker agreement is the shared recognition of the Impact AI Summit’s importance. Overall consensus among speakers is limited due to the single substantive voice, but the depth of agreement within that voice signals a clear policy direction for India.
Low inter‑speaker consensus (only one substantive speaker), but high intra‑speaker coherence, implying that if the agenda moves forward, the outlined strategic pillars are likely to be pursued collectively across government, academia, and industry.
The transcript contains only an introductory welcome by Speaker 1 and a single, uninterrupted keynote by Kiran Mazumdar‑Shaw. No other speakers present opposing viewpoints, and the speaker does not articulate any counter‑arguments to her own positions. Consequently, there are no observable disagreements or partial agreements among participants.
Minimal – the discussion is essentially a monologue, so disagreement does not affect the thematic focus on AI‑driven biotech sovereignty.
Kiran Mazumdar‑Shaw’s monologue is structured around a series of pivotal insights that progressively broaden the conversation—from defining biotech sovereignty and biological intelligence, to illustrating natural examples, envisioning programmable biology, and finally confronting geopolitical, economic, regulatory and ethical dimensions. Each highlighted comment acts as a turning point, redirecting the audience’s focus and deepening the analysis. Collectively, these remarks shape the discussion into a comprehensive roadmap that links scientific possibility with national strategy, urging coordinated action across government, academia and industry while foregrounding responsible, sovereign AI development.
Disclaimer: This is not an official session record. DiploAI generates these resources from audiovisual recordings, and they are presented as-is, including potential errors. Due to logistical challenges, such as discrepancies in audio/video or transcripts, names may be misspelled. We strive for accuracy to the best of our ability.
Related event
